Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.62 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.61 |
| ▸ | CA2 | P00918 | 3/20 | 0.55 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.54 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.53 |
| ▸ | HTR1A | P08908 | 1/20 | 0.53 |
| ▸ | DRD1 | P21728 | 1/20 | 0.53 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | DRD3 | P35462 | 1/20 | 0.53 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.53 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.53 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.53 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.53 |
| ▸ | SCN1A | P35498 | 1/20 | 0.53 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.53 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12602022 | 0.89 | POLB (0.59) | POLBESR2HTTCA2MTNR1A | |
| SCHEMBL31061980 | 0.85 | POLB (0.61) | POLBESR2HTTCA2MTNR1A | |
| SCHEMBL2631380 | 0.85 | POLB (0.61) | POLBESR2HTTCA2MTNR1A | |
| SCHEMBL172391 | 0.85 | POLB (0.61) | POLBESR2HTTCA2MTNR1A | |
| SCHEMBL9413175 | 0.84 | POLB (0.74) | POLBESR2HTTCA2MTNR1A | |
| SCHEMBL8788249 | 0.81 | HTT (0.61) | POLBESR2HTTCA2MTNR1A | |
| SCHEMBL406531 | 0.81 | HTT (0.61) | POLBESR2HTTCA2MTNR1A | |
| SCHEMBL5871673 | 0.81 | HTT (0.61) | POLBESR2HTTCA2MTNR1A | |
| Methyl Alcohol SCHEMBL10973093 | 0.81 | POLB (0.58) | POLBESR2HTTCA2MTNR1A | |
| SCHEMBL1568393 | 0.81 | HTT (0.66) | POLBHTTCA2MTNR1AADRA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11053260-B2 | Tri-cycle compound and applications thereof | FUJIAN COSUNTER PHARMACEUTICAL CO., LTD. (CN) | 2021-07-06 | — | — | US | disclosed |
| US-20200247819-A1 | TRI-CYCLE COMPOUND AND APPLICATIONS THEREOF | FUJIAN AKEYLINK BIOTECHNOLOGY CO., LTD. (CN) | 2020-08-06 | — | — | US | disclosed |
| EP-2303270-B1 | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2017-05-17 | — | — | EP | disclosed |
| US-20160272577-A1 | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI SA (FR) | 2016-09-22 | — | — | US | disclosed |
| US-9328071-B2 | Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals | SANOFI (FR) | 2016-05-03 | — | — | US | disclosed |
| US-20140309264-A1 | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | SANOFI (FR) | 2014-10-16 | — | — | US | disclosed |
| US-8445530-B2 | Acylamino-substituted fused cyclopentanecarboxylic acid derivatives and their use as pharmaceuticals | SANOFI (FR) | 2013-05-21 | — | — | US | disclosed |
| US-8436028-B2 | CETP inhibitors derived from benzoxazole arylamides | MERCK SHARP & DOHME CORP (US) | 2013-05-07 | — | — | US | disclosed |
| US-8344138-B2 | Triazinedione derivatives as GABAB receptor modulators | ADDEX PHARMA S.A. (CH) | 2013-01-01 | — | — | US | disclosed |
| US-20110230468-A1 | FUSED HETEROCYCLIC COMPOUNDS AND USES THEREOF | BRISTOL-MYERS SQUIBB COMPANY | 2011-09-22 | — | — | US | disclosed |
| US-20100331348-A1 | TROPANE DERIVATIVES USEFUL AS PESTICIDES | SYNGENTA CROP PROTECTION, INC. (US) | 2010-12-30 | — | — | US | disclosed |
| US-20100197630-A1 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES | MERCK & CO., INC | 2010-08-05 | — | — | US | disclosed |
| US-20100004246-A1 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABAB RECEPTOR MODULATORS | ADDEX PHARMA SA (CH) | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100004246-A1 | NOVEL TRIAZINEDIONE DERIVATIVES AS GABAB RECEPTOR MODULATORS | CHRNA5, GABRA5, GABRB3 | POLB 2324/4885ESR2 680/4885HTT 3215/4885 |
| US-20200247819-A1 | TRI-CYCLE COMPOUND AND APPLICATIONS THEREOF | SLC10A1, NR1H4, HAVCR2 | POLB 170/4885ESR2 2504/4885HTT 1159/4885 |
| US-20110230468-A1 | FUSED HETEROCYCLIC COMPOUNDS AND USES THEREOF | MCL1, FPR1, LTC4S | POLB 3077/4885ESR2 447/4885HTT 4336/4885 |
| US-20160272577-A1 | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | EDF1, LPAR2, LIPG | POLB 4747/4885ESR2 157/4885HTT 4545/4885 |
| US-20100331348-A1 | TROPANE DERIVATIVES USEFUL AS PESTICIDES | DDT, ACHE, TPM3 | POLB 4774/4885ESR2 1697/4885HTT 2037/4885 |
| US-20140309264-A1 | ACYLAMINO-SUBSTITUTED FUSED CYCLOPENTANECARBOXYLIC ACID DERIVATIVES AND THEIR USE AS PHARMACEUTICALS | EDF1, LPAR2, LIPG | POLB 4747/4885ESR2 157/4885HTT 4545/4885 |
| US-11053260-B2 | Tri-cycle compound and applications thereof | SLC10A1, NR1H4, HAVCR2 | POLB 170/4885ESR2 2504/4885HTT 1159/4885 |
| US-20100197630-A1 | CETP INHIBITORS DERIVED FROM BENZOXAZOLE ARYLAMIDES | CETP, APOB, MTTP | POLB 1879/4885ESR2 943/4885HTT 2846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.